通过MEK/ERK信号传递,TIPE2可以抑制黑色素瘤的进展
Xin Gao1, Yan Li2, Congcong Wang2
1School of Clinical Medicine, Weifang Medical University, Weifang, China.
Scientific reports
|November 12, 2024
概括
瘤抑制剂二 (TIPE2) 在黑色素瘤中是下调调节的. 过度表达TIPE2抑制了黑色素瘤细胞的增殖和迁移,这表明TIPE2是黑色素瘤治疗的潜在治疗标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 瘤抑制剂二 (TIPE2) 已与癌症的发展有关.
- 在黑色素瘤发病过程中TIPE2的特定作用仍未得到充分研究.
研究的目的:
- 研究TIPE2在黑色素瘤发展中的功能作用和机制.
- 为了评估黑色素瘤组织中的TIPE2表达水平,与相邻的非癌症组织相比.
主要方法:
- 在偏癌和黑色素瘤组织中对TIPE2表达的定量分析.
- 使用黑色素瘤细胞系进行体外研究,以评估TIPE2过度表达时的增殖,殖民地形成和迁移 (CCK8试验,殖民地形成试验,伤口愈合试验).
- 在体内对裸体小鼠进行瘤形成研究和免疫组织化学研究,以验证发现并评估途径参与 (MEK/ERK酸化).
主要成果:
- 与癌组织相比,TIPE2表达在黑色素瘤组织中显著下调.
- 在体外,TIPE2的过度表达明显抑制了黑色素瘤细胞的增殖,殖民地形成和迁移.
- 在体内实验证实,TIPE2过度表达抑制了瘤形成,并减少了MEK/ERK酸化.
结论:
- TIPE2 作为黑色素瘤细胞增殖和迁移的抑制剂.
- 在黑色素瘤中,MEK/ERK信号通路可能受到TIPE2的调节.
- 在抑制黑色素瘤生长方面,TIPE2 是一个有前途的治疗标.
相关概念视频
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
MAPK Signaling Cascades
5.2K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.2K


